Role of flavin-containing monooxygenase in drug development

Expert Opinion on Drug Metabolism and Toxicology

Volumn 4, Issue 12, 2008, Pages 1507-1521

  Cashman, John R ^a  

^a HUMAN BIOMOLECULAR RESEARCH INSTITUTE   (United States)

Author keywords

Animal models of metabolism; Drug design and development; Flavin containing monooxygenase; Retro reductases

Indexed keywords

ALDEHYDE OXIDASE; AMPHETAMINE; ARSENITE SODIUM; BRUCINE; CARBON MONOXIDE; COPPER SULFATE; CYCLOBENZAPRINE; CYTOCHROME P450; DICOUMAROL; DIMETHYLANILINE MONOOXYGENASE; HYDROXYLAMINE; IMIPRAMINOXIDE; MENADIONE; METHAMPHETAMINE; POTASSIUM CYANIDE; PROADIFEN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TAMOXIFEN; TRIMETHYLAMINE OXIDE; VERAPAMIL;

DRUG DESIGN; DRUG IDENTIFICATION; DRUG METABOLISM; DRUG RESEARCH; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; OXYGENATION; POLARIZATION; PROTEIN FAMILY; PROTEIN SYNTHESIS INHIBITION; REVIEW; STRUCTURE ANALYSIS;

ANIMALS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; DRUGS, INVESTIGATIONAL; HUMANS; MOLECULAR STRUCTURE; OXYGENASES;

ANIMALIA;

EID: 58149202381     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425250802522188     Document Type: Review

References (44)

1. Cashman JR. Structural and catalytic properties of the mammalian flavin-containing monooxygenase. Chem Res Toxicol 1995;8(2):166-81
2. Krueger SK, Williams DE. Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism. Pharmacol Ther 2005;106(3):357-87
3. Cashman JR, Zhang J. Human flavin-containing monooxygenases. Annu Rev Pharmacol Toxicol 2006;46:65-100
4. Ziegler DM. Flavin-containing monooxygenases: enzymes adapted for multisubstrate specificity. Annu Rev Pharmacol Toxicol 1993;33:179-99
5. Hernandez D, Janmohamed A, Chandan P, et al. Organization and evolution of the flavin-containing monooxygenase genes of human and mouse: identification of novel gene and pseudogene clusters. Pharmacogenetics 2004;14(2):117-30
6. Hines RN, Hopp KA, Franco J, et al. Alternative processing of the human FMO6 gene renders transcripts incapable of encoding a fiinctional flavin-containing monooxygenase. Mol Pharmacol 2002;62(2):320-5
7. Furnes B, Feng J, Sommer SS, Schlenk D. Identification of novel variants of the flavin-containing monooxygenase gene family in African Americans. Drug Metab Dispos 2003;31(2):187-93
8. Koukouritaki SB, Simpson P, Yeung CK, et al. Human hepatic flavin-containing monooxygenase 1 (FMO1) and 3 (FMO3) development expression. Pediatric Res 2002;51(2):236-43
9. Ziegler DM. Flavin-containing monooxygenases: catalytic mechanism and substrate specificities. Drug Metab Rev 1988;19:1-12
10. Ziegler DM. In: Enzymatic basis of detoxication. Edition, Jakoby WB. Academic Press, New York, 1980;1. p. 201-77
11. Bruice TC, Noar JB, Ball SS, Venkataram UV. Monooxygen donation potential of 4a-hydroperoxyflavins as compared with those of percarboxylic acid and other hydroperoxides. Monooxygen donation to olefin, tertiary amine, alkyl sulfide, and iodide ion. J Am Chem Soc 1983;105:2452-63
12. Cashman JR, Park SB, Berkman CE, Cashman LE. Role of hepatic flavin-containing monooxygenase 3 in drug and chemical metabolism in adult humans. Chem Biol Interact 1995;96:33-146
13. Cashman JR. The implications of polymorphisms in mammalian flavin-containing monooxygenases in drug discovery and development. Drug Discov Today 2004;9(13):574-81
14. Cashman JR. Some distinctions between flavin-containing and cytochrome P450 monooxygenases. Biochem Biophys Res Commun 2005;338(1):599-604
15. Kreiter PA, Ziegler DM, Hill KE, Burke RF. Increased biliary GSSG efflux from rat livers perfused with thiocarbamide substrates for the flavin-containing monooxygenases. Mol Pharmacol 1984;26:122-7
16. Ziegler DM. Recent studies on the structure and function of multisubstrate flavin-containing monooxygenases. Annu Rev Pharmacol Toxicol 1993;33:179-99
17. Cashman JR. The role of flavin-containing monooxygenases in drug metabolism and development. Curr Opin Drug Discov 2003;6(4):486-93
18. Cashman JR. In vitro Metabolism: FMO and related oxygenations. In: Handbook of drug metabolism. Edition, Woolf TF. New York: Marcel Dekker, 1999; p. 477-505
19. Cashman JR, Park SB, Yang ZC, et al. Metabolism of nicotine by human liver microsomes: stereoselective formation of trans-nicotine N′-Oxide. Chem Res Toxicol 1992;5:639-46
20. Cashman JR, Yang Z, Yang L, Wrighton SA. Stereo- and regioselective N- and S-oxidation of tertiary amines and sulfides in the presence of adult human liver microsomes. Drug Metab Dispos 1993;21:492-501
21. Kedderis GL, Rickert DE. Loss of rat liver microsomal cytochrome P450 during methimazole metabolism. Role of flavin-containing monooxygenase. Drug Metab Dispos 1985;13:58-61
22. Cashman JR. Metabolism of tertiary amines by rat and hog liver microsomes: role of enzymatic cope-elimination to an N-dealkylated product. In: Progress in pharmacology and clinical pharmacology. Edition, Hlavica P, Damani LA. New York: Gustav Fischer Verlag, 1991;8. p. 117-26
23. Siddens LK, Henderson MC, Vandyke JE, et al. Characterization of mouse flavin-containing monooxygenase transcript levels in lung and liver, and activity of expressed isoforms. Biochem Pharmacol 2008;75:570-9
24. Rettie AE, Lawton MP, Sadeque AJ, et al. Prochiral sulfoxidation as a probe for multiple forms of the microsomal flavin-containing monooxygenase: studies with rabbit FMO1, FMO2, FMO3, and FMO5 expressed in Escherichia coli. Arch Biochem Biophys 1994;311:369-77
25. Cashman JR. The implications of polymorphisms in mammalian flavin-containing monooxygenases in drug discovery and development. Drug Discov Today 2001;9:574-81
26. Cashman JR. Human flavin-containing monooxygenase (form 3): polymorphisms and variation in chemical metabolism. Pharmacogenetics 2002;3:325-39
27. Falls JG, Blake BL, Cao Y, et al. Gender differences in hepatic expression of flavin-containing monooxygenase isoforms; (FMO1, FMO3, and FMO5) in mice. J Biochem Toxicol 1995;10(3):171-7
28. Zhang J, Cerny MA, Lawson M, et al. Functional activity of the mouse flavin-containing monooxygenase forms 1, 3, and 5. J Biochem Mol Toxicol 2007;21(4):206-15
29. Cashman JR. Enantioselective N-Oxygenation of verapamil by the hepatic flavin-containing monooxygenase. Mol Pharmacol 1989;36:497-503
30. Clement B, Behrens D, Moller W, Cashman JR. Reduction of amphetamine hydroxylamine and other aliphatic hydroxylamines by benzamidoxime reductase and human liver microsomes. Chem Res Toxicol 2000;13:1037-45
31. Kitamura S, Sugihara K, Tatsumi K. A unique tertiary amine N-oxide reduction system composed of quinone reductase and heme in rat liver preparations. Drug Metab Dispos 1999;27(1):92-7
32. Sugihara K, Kitamura S, Tatsumi K. S-(-)-Nicotine-1′-N-oxide reductase activity of rat liver aldehyde oxidase. Biochem Mol Biol Int 1996;40:535-41
33. Kitamura S, Tatsumi K. Involvement of liver aldehyde oxidase in the reduction of nicotinamide N-oxide. Biochem Biophys Res Commun 1984;120:602-6
34. Garattini E, Fratelli M, Terao M. Mammalian aldehyde oxidases: genetics, evolution and biochemistry. Cell Mol Life Sci 2008;65:1019-48
35. Iyanagi I, Yamazaki I. One-electron-transfer reactions in biochemical system V. Difference in mechanism of quinone reduction by the NADH dehydrogenase and the NAD(P)H dehydrogenase (DT-diaphorase). Biochim Biophys Acta 1970;216:282-94
36. Mieyall JJ, Starke DW. Hydroxylation and dealkylation reactions catalyzed by hemoglobin. Methods Enzymol 1994;231:573-98
37. Parte P, Kupfer D. Oxidation of tamoxifen by human flavin-containing monooxygenase (FMO) 1 and FMO3 to tamoxifen N-oxide and its novel reduction back to tamoxifen by cytochromes P450 and hemoglobin. Drug Metab Dispos 2005;33(10):1446-52
38. Lattard V, Buronfosse T, Lachuer J, et al. Cloning, sequencing, tissue distribution and heterologous expression of rat flavin-containing monooxygenase 3. Arch Biochem Biophys 2001;391(1):30-40
39. Lattard V, Lachuer J, Buronfosse T, et al. Physiological factors affecting the expression of FMO1 and FMO3 in the rat liver and kidney. Biochem Pharmacol 2002;63:1453-64
40. Motika MS, Zhang J, Cashman JR. Flavin-containing monooxygenase 3 and human disease. Expert Opin Drug Metab Toxicol 2007;3(6):831-45
41. Al-Waiz M, Ayesh R, Mitchell SC, et al. Disclosure of the metabolic retroversion of trimethylamine N-oxide in humans: a pharmacogenetic approach. Clin Pharmacol Ther 1987;42:608-12
42. Cashman JR, Camp K, Fakharzadeh SS, et al. Biochemical and clinical aspects of the human flavin-containing monooxygenase form 3 (FMO3) related to trimethylaminuria. Current Drug Metabolism 2003;4:151-70
43. Kadlubar FF, Mckee EM, Ziegler DM. Reduced pyridine nucleotide-dependent N-hydroxy amine oxidase and reductase activities of hepatic microsomes. Arch Biochem Biophys 1973;156:46-57
44. Hernandez D, Chandan P, Janmohamed A, et al. In: Cytochrome P450 protocols. 2nd Edition, Philips IR, Shephard EA, editors. Humana Press, New Jersey, 2006; p. 307-19